本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/5/16 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 个月 12 | | 预计回购金额 | 60,000万元~120,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 858.41万股 | | 累计已回购股数占总股本比例 | 0.13% | | 累计已回购金额 | 37,625.11万元 | | 实际回购价格区间 | 39.00元/股~57.01元/股 | 一、回购股份的基本情况 江苏恒瑞医药股份有限公司（以下简称"公司"）于 2024 年 5 月 15 日召开 第九届董事会第八次会议审议通过了《关于以集中竞价交易方式回购公司股份方 案的议案》，同意公司使用自有资金，以集中竞价交易方式回购公司股份用于实 施员工持股计划。回购价格不超过人民币 67.38 元/股（含），回购资金 ...

Market Performance - The Shanghai Composite Index rose by 1.13% to 3316.11 points, while the Shenzhen Component increased by 1.84% and the ChiNext Index gained 1.97%[1] - The Hang Seng Index climbed 0.7% to 22662.71 points, with the Hang Seng China Enterprises Index up by 0.37%[1] - The total market turnover in Hong Kong reached 213.4 billion HKD[1] Trade Negotiations - High-level trade talks between the U.S. and China are set to begin this weekend, marking the first confirmed negotiations since the imposition of tariffs by the Trump administration[8] - U.S. Treasury Secretary Scott Bessen and Trade Representative Jamison Greer will meet with Chinese Vice Premier He Lifeng in Switzerland[12] Economic Indicators - The U.S. Dow Jones Industrial Average fell by 0.95%, while the S&P 500 dropped by 0.77% to 5606.91 points, and the Nasdaq decreased by 0.87%[1] - The European stock indices showed mixed results, with no clear trend established[1] Financial Policies - The People's Bank of China and other financial regulators are scheduled to hold a press conference to discuss measures aimed at stabilizing the market[1]

Group 1: CATL (宁德时代) - CATL is a global leader in the innovation of new energy technology, primarily engaged in the research, production, and sales of power batteries and energy storage batteries [1][2] - The company has maintained the number one global market share in power batteries for eight consecutive years, with a projected market share of 37.9% in 2024; it also ranks first in energy storage batteries for four years, with a projected market share of 37% in 2024 [1][2] - As of the end of 2024, CATL has established six R&D centers and thirteen battery manufacturing bases globally, serving 64 countries and regions, with over 1.7 million electric vehicles equipped with CATL batteries [1][2] Group 2: Financial Performance of CATL - CATL's revenue for 2022, 2023, and 2024 is projected to be RMB 328.59 billion, RMB 400.92 billion, and RMB 362.01 billion, respectively, with net profits of RMB 33.46 billion, RMB 47.34 billion, and RMB 55.30 billion [2] - In 2024, 30.5% of the company's revenue is expected to come from overseas markets [2] Group 3: Hengrui Medicine (恒瑞医药) - Hengrui Medicine, founded in the early 1970s, focuses on multiple therapeutic areas, including oncology, metabolism, cardiovascular diseases, immunology, and neuroscience, with over 110 commercialized drugs [3][4] - The company's revenue for 2022, 2023, and 2024 is projected to be RMB 21.27 billion, RMB 22.82 billion, and RMB 27.98 billion, respectively, with a compound annual growth rate exceeding 14%, significantly higher than the global pharmaceutical market's growth rate of about 4% [3][4] - Hengrui has established 14 global R&D centers and has initiated over 20 overseas clinical trials, with products commercialized in over 40 countries [4] Group 4: Strategic Initiatives of Hengrui Medicine - The company has a pipeline of over 90 candidate new molecular entity innovative drugs and has engaged in 14 licensing transactions with global partners since 2018, totaling approximately USD 14 billion [4] - Hengrui Medicine emphasizes a "dual-driven strategy" of "innovation + internationalization," positioning internationalization as a key focus for growth [4][5]

Core Viewpoint - The impact of the U.S. "reciprocal tariffs" on Chinese pharmaceutical companies is limited, with many companies reporting normal operations and minimal effects on their business [1][2][4][7][12]. Group 1: Company Responses - Heng Rui Pharmaceutical reported that overseas sales account for only 2.56% of its revenue, indicating that U.S. tariffs have a minimal impact on its business [1]. - Han Yu Pharmaceutical stated that it has a diversified market presence across North America, Asia, Europe, and South America, which mitigates risks from single market policy changes [2]. - Bai Yang Pharmaceutical noted that its supply chain is globally diversified, and the impact of tariffs is minimal [3]. - WuXi AppTec acknowledged that tariffs will have some impact but emphasized their optimized supply chain and management practices to minimize effects [4]. - Kangtai Biological confirmed that it has no products exported to the U.S. and is focusing on markets along the Belt and Road [5]. Group 2: Industry Trends - The medical device industry in China is rapidly developing, with companies like Mindray Medical actively seeking alternatives for U.S. imported raw materials [5]. - Companies are increasingly focusing on domestic production and local supply chains to counteract potential tariff impacts [6][8]. - The vaccine industry in China is evolving, with companies like CanSino Biologics transitioning from followers to leaders in vaccine technology [8][9]. - The overall sentiment among Chinese pharmaceutical companies is that the current tariff situation presents an opportunity for domestic substitution and innovation [10][12].

Core Viewpoint - Hanbang Technology (688755.SH) is set to be listed on the Sci-Tech Innovation Board, focusing on chromatography technology to provide separation and purification equipment and solutions for the pharmaceutical and life sciences sectors [1][2] Company Overview - Hanbang Technology is a high-tech enterprise integrating R&D, production, and sales, primarily serving the pharmaceutical and life sciences industries [1] - The company has established itself as a leading player in the domestic chromatography purification equipment market, with a market share of approximately 12.7% in small molecule liquid chromatography equipment, ranking first among domestic manufacturers [6] - Hanbang's product lines include small molecule and large molecule drug separation and purification equipment, catering to both industrial production and laboratory research [6] Financial Information - The company's initial public offering (IPO) price is set at 22.77 CNY per share, with an institutional offering price of 23.00 CNY per share, resulting in a market capitalization of 15.03 billion CNY [5] - The projected use of raised funds includes investments in various production projects, with amounts allocated as follows: 1.93 billion CNY for annual production of 1,000 liquid chromatography separation equipment, 1.81 billion CNY for chromatography equipment R&D center, and 2.25 billion CNY for annual production of 2,000 laboratory chromatography purification instruments [5] Market Position and Competitors - Hanbang Technology has established strong partnerships with well-known pharmaceutical companies such as Hengrui Medicine, Zhengda Tianqing, and others, and its products are exported to multiple countries including Germany, the UK, India, and South Korea [6] - The company has undergone multiple rounds of financing, with notable investors including WuXi AppTec, Junlian Capital, and Sequoia Capital [6] Risks and Challenges - The company has reported high ending inventory amounts and potential impairment risks, with inventory values of 508 million CNY, 431 million CNY, and 387 million CNY from 2022 to 2024 [7] - Accounts receivable values are also significant, with amounts of 131 million CNY, 119 million CNY, and 130 million CNY for the same period, indicating a high proportion of overdue accounts [7]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600276 证券简称：恒瑞医药 公告编号：临2025-072 江苏恒瑞医药股份有限公司 关于刊发境外上市外资股（H股）发行聆讯后资料集的公告 鉴于聆讯后资料集的刊发目的仅为提供信息予香港公众人士和合资格的投资者，公司将不会在境内证券 交易所的网站和符合监管机构规定条件的媒体上刊登该聆讯后资料集，但为使A股投资者及时了解该聆 讯后资料集披露的本次发行上市及公司的其他相关信息，现提供该聆讯后资料集在香港联交所网站的查 询链接： 中文： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 江苏恒瑞医药股份有限公司（以下简称"公司"）正在进行发行境外上市外资股（H股）股票并在香港联 合交易所有限公司（以下简称"香港联交所"）主板挂牌上市（以下简称"本次发行上市"）的相关工作。 2025年1月6日，公司向香港联交所递交了本次发行上市的申请，并于同日在香港联交所网站刊登了申请 资料。 2025年4月28日，中国证券监督管理委员会就公司本次发行上市出具《关于江苏恒瑞医药股份有限公司 ...

自A股上市以来累计现金分红约人民币80.29亿元。 本文为IPO早知道原创 作者｜ 罗宾 微信公众号｜ipozaozhidao 商业化层面， 截至 2024 年 12 月 31 日 ，公司已建立起约 9,000 人的自建销售和营销团队，在中 国制药企业中规模领先。销售网络覆盖中国 30 多个省级行政区的超过 22,000 家医院以及超过 200,000 家线下零售药店， 处于 行业领先 地位 。 近年来，恒瑞 加速全球化扩张步伐，充分释放产品矩阵和技术平台的潜力。 公司 已在包括美国、欧 洲、澳大利亚、日本及韩国等地区启动超过 20 项海外临床试验，产品在 40 多个国家实现商业化。 自 2018 年以来，公司与全球合作伙伴达成了 14 笔对外许可交易，涉及 17 个分子实体，总交易额 高达约 140 亿美元，首付款总额约为 6 亿 美元， 同时 还获 得 了若干合作伙伴的股权。 公司 于 2024 年 收入 录得 人民币 280 亿元，自 2014 年起的复合年增长率约为 14% ，远超同期 全球制药市场约 4% 的复合年增长率。创新药已成为公司收入的主要来源之一，其销售收入占总收 入的百分比从 2022 ...

伴随着赴港潮的出现，越来越多A股公司正在登陆港股市场。 最新消息，A股龙头企业恒瑞医药（600276.SH）、宁德时代（300750.SZ）相继于5月5日、6日更新聆讯后资料集，意味着其已通过港交所聆讯，预计将很 快于港交所挂牌上市，而且有不少投资者预期这两家企业或刷新年内港股募资记录。 医药龙头赴港，业绩恢复增长 恒瑞医药早期业务以仿制药为主。然而，随着政策的变化，以及集采带来的冲击，仿制药市场的天花板日益显现。自2008年起，恒瑞医药开始向创新药研发 转型，2011年公司第一个创新药艾瑞昔布获批上市。 在经过多年的发展及持续高强度投入研发后，恒瑞医药的创新药已经覆盖传统优势的肿瘤领域。同时广泛布局了代谢和心血管疾病、免疫和呼吸系统疾病等 多个领域。根据弗若斯特沙利文的资料，这些主要治疗领域对应的全球制药市场规模占2023年全球制药市场总规模的57.4%，达8458亿美元，且预计2023年 至2028年复合年增长率达6.4%，超过同期全球制药市场5.7%的复合年增长率。 截至2025年4月23日，恒瑞医药拥有19款已上市的新分子实体创新药和逾90款处于临床及更后期阶段的新分子实体在研创新药。 值得一提的是， ...

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [8][29]. Core Insights - The industry is experiencing a return to normal growth, with a notable performance in chemical pharmaceuticals, while the overall revenue growth for 2024 is projected to decline by 0.6% year-on-year, marking the first decline in recent years [12][14]. - The report highlights a significant disparity among sectors, with chemical pharmaceuticals showing a remarkable net profit growth of 97.7%, while biological products face substantial short-term performance pressure [17][18]. - The current low allocation and valuation levels present a high cost-performance ratio for investments in the pharmaceutical sector, suggesting it is an excellent time to allocate resources [19][28]. Summary by Sections 1. Innovation in the Pharmaceutical Chain - The report notes that the impact of national procurement and anti-corruption measures is gradually diminishing, leading to a normal release of rigid demand in hospitals [11]. - The overall revenue growth for the industry in 2024 is projected at -0.6%, with net profit and non-recurring net profit declining by 8.1% and 5.9% respectively [12][13]. 2. Investment Recommendations - The report suggests focusing on the innovation drug supply chain (Biotech + CXO + upstream) and certain overseas medical devices, recommending companies such as Aosaikang, Yifang Bio, and WuXi AppTec for investment [29]. - For in-hospital products (traditional Chinese medicine, chemical pharmaceuticals, and medical devices), companies like Hengrui Medicine and Mindray Medical are highlighted as having more certain growth prospects [29]. 3. Market Positioning - The report indicates that the allocation of public fund products in pharmaceutical stocks has decreased from 11.2% in Q1 2024 to 8.7% in Q4 2024, with a slight recovery to 9.1% by Q1 2025 [19][21]. - The pharmaceutical sector's price-to-earnings ratio is at a 10-year low, suggesting potential for growth as innovative products continue to emerge [22][24].

Core Insights - The report indicates a gradual market recovery, shifting from short-term volatility to a fundamental-driven market, with an overall trend expected to stabilize and improve [7][8]. Company Summaries Chengdu Bank (601838) - The bank's performance remains stable with a high dividend yield, projecting an EPS of 3.53 and a net asset value of 21.51 yuan per share for 2025 [11][12]. - In Q1 2025, revenue and net profit growth slowed to 3.17% and 5.64% respectively, primarily due to a decline in net interest margin and a significant drop in fee income [16]. - Total assets and loans grew by 13.25% and 17.26% year-on-year, driven by strong regional economic performance [16]. Zijin Mining (601899) - The company experienced significant performance improvement due to rising metal prices and production, with copper and gold production increasing by 6% and 8% respectively in 2024 [20]. - The resource reserve expansion and diversification solidify its leading position in the industry, with total resources including 11,037,000 tons of copper and 3,973 tons of gold [20]. - The company maintains a "buy" rating, with projected EPS of 1.52 for 2025 [20]. Qingdao Beer (600600) - The company is expected to perform well in the peak season, with a projected EPS of 3.52 for 2025 [21][24]. - In Q4 2024, revenue showed a year-on-year increase of 7.44%, indicating a recovery in the restaurant sector [24]. - The company is focusing on optimizing product and channel structures to enhance market competitiveness [24]. Hengrui Medicine (600276) - The company reported a stable growth in Q1 2025, with revenue increasing by 20.14% and net profit by 36.90% [28]. - The innovative drug segment is a key driver of growth, with significant contributions from newly approved products [28]. - The company is expected to maintain a "buy" rating with projected EPS of 1.05 for 2025 [28]. BYD (002594) - The company achieved a remarkable 100.38% year-on-year increase in net profit for Q1 2025, driven by strong demand in the electric vehicle market [32]. - The high-end brand strategy is gaining traction, with significant growth in sales for its premium brands [32]. - BYD is projected to maintain a "buy" rating with an EPS of 18.09 for 2025 [32]. State Grid NARI Technology (600406) - The company reported steady performance with a revenue increase of 11.15% in 2024, and a projected EPS of 1.09 for 2025 [37]. - The smart grid segment is enhancing profitability, with a focus on technological innovation and market expansion [37]. - The company is expected to maintain a "buy" rating due to its robust growth prospects [37]. Huaneng International (600011) - The company has a significant installed capacity and advanced equipment, with a focus on green and low-carbon transformation [41]. - The company is expected to achieve an EPS of 0.73 for 2025, reflecting its ongoing efforts in renewable energy [41]. - Huaneng is actively pursuing technological innovations to enhance operational efficiency [41]. Northern Huachuang (002371) - The company reported a 35.14% year-on-year increase in revenue for 2024, with a projected EPS of 14.29 for 2025 [45]. - The company is expanding its market share through technological breakthroughs and product diversification [45]. - The acquisition of Chip Source Micro is expected to enhance its competitive position in the semiconductor equipment sector [45]. China Telecom (601728) - The company is focusing on deep integration of production and data, with a projected EPS of 0.39 for 2025 [48]. - The company is expected to benefit from favorable market conditions and policy support for the telecommunications sector [48].